Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Living Cell Technologies ( (AU:1AI) ) has shared an announcement.
Algorae Pharmaceuticals has applied to the ASX for quotation of 3,852,712 additional ordinary fully paid shares, to be issued on March 13, 2026. The move increases the company’s quoted share capital, potentially enhancing liquidity for investors and reflecting the conversion or exercise of existing securities into tradable shares.
The most recent analyst rating on (AU:1AI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Living Cell Technologies stock, see the AU:1AI Stock Forecast page.
More about Living Cell Technologies
Algorae Pharmaceuticals Limited is an Australian-listed biotechnology company operating in the pharmaceuticals sector. The company’s securities trade on the ASX under the code 1AI, with ordinary fully paid shares forming its primary listed security class.
Average Trading Volume: 1,468,688
Technical Sentiment Signal: Hold
Current Market Cap: A$23.98M
For an in-depth examination of 1AI stock, go to TipRanks’ Overview page.